MARINUS PHARMACEUTICALS, INC. Income Tax Expense (Benefit) in USD from Q3 2022 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Marinus Pharmaceuticals, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q3 2022 to 2023.
  • Marinus Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2023 was -$1.54M.
  • Marinus Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2023 was -$1.54M, a 145% decline from 2022.
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)

MARINUS PHARMACEUTICALS, INC. Quarterly Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 -$1.54M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q3 2022 $1.75M Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07

MARINUS PHARMACEUTICALS, INC. Annual Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$1.54M -$4.93M -145% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-05
2022 $3.39M Jan 1, 2022 Dec 31, 2022 10-K 2024-03-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.